We are live on ! Find out more
RCMNY

Rubric Capital Management (New York) Portfolio holdings

AUM $9.44B
1-Year Est. Return 68.42%
This Fund
S&P 500
This Quarter Est. Return
+14.82%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
–
AUM
$3.38B
AUM Growth
-$1.44B
Cap. Flow
-$1.68B
Cap. Flow %
-49.61%
Top 10 Hldgs %
44.12%
Holding
72
New
14
Increased
22
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$82.8M
2
VST icon
Vistra
VST
+$60.1M
3
IBIT icon
iShares Bitcoin Trust
IBIT
+$53.7M
4
EXTR icon
Extreme Networks
EXTR
+$47M
5
FLR icon
Fluor
FLR
+$41.8M

Top Sells

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$32.3M
2
GDRX icon
GoodRx Holdings
GDRX
+$24.8M
3
KOP icon
Koppers
KOP
+$22.5M
4
ARDX icon
Ardelyx
ARDX
+$18.8M
5
COOP
Mr. Cooper
COOP
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 47.6%
2 Technology 8.46%
3 Financials 7.86%
4 Industrials 6.07%
5 Materials 5.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$41.2B
$249M 7.37%
17,669,588
-557,013
-3% -$7.02M
VTRS icon
2
Viatris
VTRS
$18.9B
$220M 6.51%
18,442,093
+874,201
+5% +$10.5M
ROIV icon
3
Roivant Sciences
ROIV
$26.2B
$211M 6.23%
20,000,000
+1,000,000
+5% +$10.8M
GLNG icon
4
Golar LNG
GLNG
$5.13B
$157M 4.63%
6,506,757
– –
BGC icon
5
BGC Group
BGC
$4.89B
$148M 4.36%
19,000,000
-1,000,000
-5% -$7.41M
COOP
6
DELISTED
Mr. Cooper
COOP
$118M 3.5%
1,518,773
-267,022
-15% -$18.6M
QDEL icon
7
QuidelOrtho
QDEL
$838M
$115M 3.4%
2,400,000
+1,419,937
+145% +$82.8M
FLR icon
8
Fluor
FLR
$7.96B
$110M 3.25%
2,600,000
+1,089,828
+72% +$41.8M
VST icon
9
Vistra
VST
$47.4B
$84.6M 2.5%
+1,213,998
New +$60.1M
CSTM icon
10
Constellium
CSTM
$3.99B
$80.3M 2.37%
3,630,347
+705,909
+24% +$13.7M
PTVE
11
DELISTED
Pactiv Evergreen Inc. Common stock
PTVE
$79.4M 2.35%
5,541,393
+501,627
+10% +$7.11M
MATV icon
12
Mativ Holdings
MATV
$711M
$75M 2.22%
4,000,000
+1,317,600
+49% +$19.7M
ARQT icon
13
Arcutis Biotherapeutics
ARQT
$3.18B
$74.4M 2.2%
7,510,000
+865,470
+13% +$6.46M
HRTX icon
14
Heron Therapeutics
HRTX
$92.9M
$74M 2.19%
26,713,503
– –
COLL icon
15
Collegium Pharmaceutical
COLL
$956M
$71.2M 2.1%
1,834,027
-924,226
-34% -$32.3M
RNW icon
16
ReNew
RNW
$2.25B
$70.3M 2.08%
11,711,700
+1,291,700
+12% +$8.51M
IBIT icon
17
iShares Bitcoin Trust
IBIT
$47.8B
$69.7M 2.06%
+1,722,497
New +$53.7M
ANIP icon
18
ANI Pharmaceuticals
ANIP
$1.78B
$66.3M 1.96%
958,533
-166,467
-15% -$10M
LBTYA icon
19
Liberty Global Class A
LBTYA
$3.6B
$65.1M 1.92%
3,845,351
+866,023
+29% +$15.8M
DOLE icon
20
Dole
DOLE
$1.32B
$61.3M 1.81%
5,141,388
+610,448
+13% +$7.08M
SSYS icon
21
Stratasys
SSYS
$774M
$58.7M 1.73%
5,050,000
+800,000
+19% +$10.3M
AMRX icon
22
Amneal Pharmaceuticals
AMRX
$5.79B
$57.8M 1.71%
9,541,948
+1,541,948
+19% +$8.7M
VYX icon
23
NCR Voyix
VYX
$1.14B
$57.4M 1.7%
4,546,081
+954,853
+27% +$13.8M
OFIX icon
24
Orthofix Medical
OFIX
$419M
$53.2M 1.57%
3,665,000
– –
ADEA icon
25
Adeia
ADEA
$3.11B
$50.7M 1.5%
4,640,009
– –
1
2 3

Similar funds

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return

Rubric Capital Management (New York)'s Q1 2024 Portfolio in Review

As of Q1 2024, Rubric Capital Management (New York) held 72 positions worth $3.38B, down 30% from $4.82B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Rubric Capital Management (New York) withdrew a net $1.68B in Q1 2024, closing 4 positions and reducing 16 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $17.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 28% a quarter earlier, followed by Technology and Financials.

Against the trend, Rubric Capital Management (New York) opened a new position in Vistra worth $84.6M.

  • Rubric Capital Management (New York)'s largest Q1 2024 buy was Vistra: 1,213,998 shares worth $84.6M.
  • Rubric Capital Management (New York) added most to QuidelOrtho in Q1 2024, an estimated $82.8M increase.
  • Rubric Capital Management (New York)'s biggest Q1 2024 reduction was Collegium Pharmaceutical, cutting an estimated $32.3M.
  • Rubric Capital Management (New York) fully exited Silk Road Medical, Inc. Common Stock in Q1 2024, selling an estimated $17.5M.
  • Rubric Capital Management (New York)'s ten largest holdings make up 44% of its $3.38B portfolio in Q1 2024.
  • Rubric Capital Management (New York) opened 14 new positions and closed 4 in Q1 2024.
  • Rubric Capital Management (New York)'s portfolio value fell 30% quarter-over-quarter to $3.38B.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2024, filed 10 May 2024.